Inflammatory pathways in ocular surface immune cells

Inflammatory pathways in ocular surface immune cells refer to the complex network of signaling cascades—such as the NF-κB, MAPK, and JAK/STAT pathways—that drive immune-mediated damage to the cornea and conjunctiva (Stern et al., 2013, Investigative Ophthalmology & Visual Science). These pathways are central to the pathogenesis of Dry Eye Disease (DED), where environmental or systemic triggers initiate a self-perpetuating cycle of desiccating stress, cytokine release (e.g., TNF-α, IL-1β), and the recruitment of Th1 and Th17 T-lymphocytes (Perez et al., 2020, The Ocular Surface). The activation of these immune cells leads to further ocular surface damage and a breakdown of the tear film's homeostatic balance. Therapeutic intervention focuses on disrupting this cycle using agents like Cyclosporine, which inhibits T-cell cytokine production, or Lifitegrast, which prevents T-cell adhesion and migration to the ocular surface (Bron et al., 2017, The Ocular Surface). Monitoring these pathways often involves measuring inflammatory markers like MMP-9 or cellular markers like HLA-DR to assess disease severity and treatment efficacy (Rolando et al., 2010, Current Opinion in Allergy and Clinical Immunology).

Other names

Ocular surface inflammationImmune-mediated ocular surface disease pathwaysVicious cycle of dry eye inflammation

Modulation of these pathways is achieved through various mechanisms, including the inhibition of calcineurin to prevent T-cell activation (Cyclosporine), the blockade of LFA-1/ICAM-1 interactions to inhibit T-cell recruitment (Lifitegrast), and the activation of glucocorticoid receptors to suppress the expression of pro-inflammatory genes (Corticosteroids) (Oda et al., 2023, Journal of Clinical Medicine; Perez et al., 2020, The Ocular Surface).